相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
Jamal Majidpoor et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
(Im)maturity in Tumor Ecosystem
Keywan Mortezaee et al.
FRONTIERS IN ONCOLOGY (2022)
Redox tolerance and metabolic reprogramming in solid tumors
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Keywan Mortezaee et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
The impact of hypoxia on immune state in cancer
Keywan Mortezaee et al.
LIFE SCIENCES (2021)
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
Nizar M. Tannir et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor et al.
CLINICAL IMMUNOLOGY (2021)
Organ tropism in solid tumor metastasis: an updated review
Keywan Mortezaee
FUTURE ONCOLOGY (2021)
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
Eric J. Hsu et al.
NATURE COMMUNICATIONS (2021)
Angiogenesis as a hallmark of solid tumors-clinical perspectives
Jamal Majidpoor et al.
CELLULAR ONCOLOGY (2021)
Normalization in tumor ecosystem: Opportunities and challenges
Keywan Mortezaee
CELL BIOLOGY INTERNATIONAL (2021)
Expressivity of Interleukin-8 and Gastric Cancer Prognosis Susceptibility: A Systematic Review and Meta-Analysis
Zhenzhen Wang et al.
DOSE-RESPONSE (2021)
Interleukin-2 therapy of cancer-clinical perspectives
Jamal Majidpoor et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
LIFE SCIENCES (2021)
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
Victor Cervera-Carrascon et al.
FRONTIERS IN IMMUNOLOGY (2021)
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment
I-Ying Kuo et al.
THERANOSTICS (2021)
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression
Zoila A. Lopez-Bujanda et al.
NATURE CANCER (2021)
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells
J. M. R. Van der Meer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
A37 N-803 Plus Nivolumab for Advanced or Metastatic Non-Small Cell Lung Cancer: Update on Phase II Experience of Combination PD1 Blockade with an IL-15 Superagonist
J. Wrangle et al.
Journal of Thoracic Oncology (2020)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma et al.
NATURE COMMUNICATIONS (2020)
Significance of the IL-8 pathway for immunotherapy
Manuela Gonzalez-Aparicio et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 α-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression
Maria Saveria Gilardini Montani et al.
BRITISH JOURNAL OF CANCER (2020)
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Alain P. Algazi et al.
CLINICAL CANCER RESEARCH (2020)
Rationale for IL-15 superagonists in cancer immunotherapy
Karin M. Knudson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity
Shanling Shen et al.
FRONTIERS IN IMMUNOLOGY (2020)
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Brian Diskin et al.
NATURE IMMUNOLOGY (2020)
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C. Yuen et al.
NATURE MEDICINE (2020)
Immune escape: A critical hallmark in solid tumors
Keywan Mortezaee
LIFE SCIENCES (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
Emilio Francesco Giunta et al.
SCIENTIFIC REPORTS (2020)
Localized Interleukin-12 for Cancer Immunotherapy
Khue G. Nguyen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung A. Oh et al.
NATURE CANCER (2020)
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Da Hyun Kang et al.
IMMUNE NETWORK (2020)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells
Yujiro Toyoshima et al.
CANCER IMMUNOLOGY RESEARCH (2019)
1222PEvaluation of the anti-tumour efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
K C Hicks et al.
ANNALS OF ONCOLOGY (2019)
Targets for improving tumor response to radiotherapy
Keywan Mortezaee et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry
Yu-Kuan Huang et al.
NATURE COMMUNICATIONS (2019)
PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer
Hiroaki Saito et al.
ANTICANCER RESEARCH (2019)
PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
Jiaqiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Nasser Hashemi Goradel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
Caroline Jochems et al.
ONCOIMMUNOLOGY (2019)
NADPH Oxidase as a Target for Modulation of Radiation Response; Implications to Carcinogenesis and Radiotherapy
Keywan Mortezaee et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Keywan Mortezaee et al.
CURRENT CLINICAL PHARMACOLOGY (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
Katherine E. Lewis et al.
ONCOIMMUNOLOGY (2018)
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment
Hirotake Tsukamoto et al.
CANCER RESEARCH (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Role of PD-1 during effector CD8 T cell differentiation
Eunseon Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors
Hyungseok Seo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
Michael Carleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis
Li Sun et al.
CELL DEATH & DISEASE (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al.
CANCER CELL (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
PD-L1 blockade enhances anti-tumor efficacy of NK cells
Jeremiah L. Oyer et al.
ONCOIMMUNOLOGY (2018)
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
M. Felices et al.
GYNECOLOGIC ONCOLOGY (2017)
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Sang Taek Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu et al.
CLINICAL CANCER RESEARCH (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
Hu Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
Erin E. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
Shunsuke Chikuma et al.
JOURNAL OF IMMUNOLOGY (2009)
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
Franz O. Smith et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
